- Kenneth W. Freeman to Continue as Chairman of the Board -
- John C. Baldwin, M.D., Elected to Board of Directors -
TETERBORO, N.J., May 4 /PRNewswire-FirstCall/ -- Quest Diagnostics
Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing,
information and services, announced today that Surya N. Mohapatra, Ph.D., was
appointed President and Chief Executive Officer, completing the CEO succession
plan announced in November, 2003. Dr. Mohapatra succeeds Kenneth W. Freeman,
who will continue as Chairman of the Board through December 14, 2004.
In addition, John C. Baldwin, M.D., was elected to the Board of Directors
by stockholders at the company's 2004 Annual Meeting of Stockholders.
Separately, as previously announced, two Directors whose terms expired at the
2004 annual meeting, Kenneth D. Brody and Mary A. Cirillo, retired from the
Board of Directors. Together, this reduces the number of directors from 11 to
10.
Dr. Baldwin is Associate Provost for Health Affairs at Dartmouth College
and Professor of Surgery at Dartmouth Medical School. From 1994 to 1998, Dr.
Baldwin was the head of the surgical programs at Baylor College of Medicine
and its affiliated hospitals. Dr. Baldwin was also the Governor of the
American College of Surgeons from 1991 through 1997 and the President of the
International Society of Cardiothoracic Surgeons in 1999. Dr. Baldwin served
on the Board of Overseers of Harvard University from 1995 to 2001 and was
elected Vice-Chair during the last year of his term.
"Dr. Baldwin's many accomplishments and insights in the world of medicine
and science will prove invaluable as Quest Diagnostics evolves in the future,"
said Kenneth W. Freeman, Chairman of the Board. "We are pleased to welcome him
to our Board."
Quest Diagnostics Incorporated is the nation's leading provider of
diagnostic testing, information and services, providing insights that enable
healthcare professionals to make decisions that improve health. The company
offers the broadest access to diagnostic testing services through its national
network of laboratories and patient service centers, and provides interpretive
consultation through its extensive medical and scientific staff. Quest
Diagnostics is the leading provider of esoteric testing, including gene-based
medical testing, and provides advanced information technology solutions to
improve patient care. Additional company information is available at:
www.questdiagnostics.com
The statements in this press release which are not historical facts or
information may be forward-looking statements. These forward-looking
statements involve risks and uncertainties that could cause actual results and
outcomes to be materially different. Certain of these risks and uncertainties
may include, but are not limited to, competitive environment, changes in
government regulations, changing relationships with customers, payers,
suppliers and strategic partners and other factors described in the Quest
Diagnostics Incorporated 2003 Form 10-K and subsequent filings.
SOURCE Quest Diagnostics Incorporated
-0- 05/04/2004
/CONTACT: Investors, Laure Park, +1-201-393-5030, or Media, Gary Samuels,
+1-201-393-5700, both of Quest Diagnostics Incorporated/
/Web site: http://www.questdiagnostics.com /
(DGX)
CO: Quest Diagnostics Incorporated
ST: New Jersey